● Recruiting

Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)

Condition: Myelofibrosis (MF) · Chronic Myelomonocytic Leukemia (CMML) · Sponsor: M.D. Anderson Cancer Center

PhasePhase 1/Phase 2

Planned participants66

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

* To find the recommended dose of axatilimab given alone and in combination with ruxolitinib in patients with MF and CMML. * To learn if axatilimab given in combination with ruxolitinib can help to control MF and CMML.

This description comes directly from the study's public registry record.

Talk to the study team

Naveen Pemmaraju, MD · (713) 792-4956 · npemmaraju@mdanderson.org

Always discuss trial participation with your own doctor first.

Locations (1)

The University of Texas M. D. Anderson Cancer Center

Houston, Texas, United States

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07128381